13. Dell'Italia LJ, Meng QC, Balcells E, Wei CC, Palmer R, Hageman GR, at al.Compartmentalization of angiotensin II generation in the dog heart- Evidence forindependent mechanisms in intravascular and interstitial spaces. J Clin Invest1997;100:253-8.14. Campbell DJ. Circulating and tissue angiotensin systems. J Clin Invest 1987;79:1-6.15. Engeli S, Negrel R, Sharma AM. Physiology and pathophysiology of the adiposetissue renin-angiotensin system. Hypertension 2000;35:1270-7.16. Johnston CI. Renin-angiotensin system: a dual tissue and hormonal system forcardiovascular control. J Hypertens 1992; Suppl 10:513-26.17. Navar LG, Harrison-Bernard LM, Nishiyama A, Kobori H. Regulation of intrarenalangiotensin II in hypertension. Hypertension 2002;39:316-22.18. Dostal DE. The cardiac renin-angiotensin system: novel signaling mechanisms relatedto cardiac growth and function. Regul Pept 2000;91:1-11.19. Matsubara H. Pathophysiological role angiotensin II type 2 receptor in cardiovascularand renal deseae. Cir Res 1998;83:1182-91.20. Igić R, Kojović V. Angiotensin i converting enzyme (kininase II) in ocular tissues.Exp Eye Res 1980;30:299-303.21. Re RN. Implications of intracrine hormone action for physiology and medicine. Am JPhysiol Heart Circ Physiol 2003;284:H751-7.22. Yang Z, Bove CM, French BA, Epstein FH, Berr S, DiMaria JM, et al. Angiotensin IItype 2 receptors over-expression preserves left ventricular function after myocardialinfarction. Circulation 2002;106:106-11.23. Su J-Z, Fukuda N, Jin X-Q, Lai Y-M, Suzuki R, Tahira Y, et al. Effect of AT 2 receptoron expression of AT 1 and TGF-β receptors in VSMC's from SHR. Hypertension2002;40:853-8.24. Carey RM, Wang Z-Q, Siragy HM. Role of the angiotensin type 2 receptor in theregulation of blood pressure and renal function. Hypertension 2000;35:155-63.25. AbdAlla S, Lother H et Massiery A, Quitterer U. Increased AT1 receptor heterodimersin preeclampsia mediate enhanced angiotensin II responsiveness. Nat Med2001;7:1003-9.26. Hsueh WA, Baxster JD. Human prorenin. Hypertension 1991;17:469-79.27. Osmond DH, Sealey JE, McKenzie JK. Activation and function of prorenin: differentviewpoints. Can J Physiol Pharmacol 1991;69:1308-14.107
28. Sealey JE. Plasma renin activity and plasma prorenin assays. Clin Chem1991;37:1811-19.29. Itskovitz J, Rubattu S, Rosenwaks Z, Liu HC, Sealey JE. Relationship of follicularfluid prorenin to oocyte maturation, steroid levels, and outcome on in vitrofertilization. J Clin Endocrinol Metab 1991; 72:165-71.30. Wilson DM, Luetscher JA. Plasma prorenin activity and complications in childrenwith insulin-dependent diabetes mellitus. N Enl J Med 1990;323:1101-6.31. Skott O, Jensen BL. Cellular and intravenal control of renin secretion. Clin Sci1993;84:1-10.32. Opshal JA, Smith KL, Murray RD, Abraham PA, Katz SA. Renin and renin inhibitionin anephric man. Clin Exp Hypertens 1993;15:289-306.33. Van Dongen R, Peart WS. Calcium dependence of the inhibitory effect of angiotensinon renin secretion in the isolated perfused kidney of the rat. Br J Pharmac1974;52:125-9.34. Vandr AJ, Miller R. Control of renin secretion in the anesthetized dogs. Am J Physiol1964;207:537-45.35. Humphreys MH, Reid IA, Ufferman RG, Lieberman RA, Earley LE. The relationshipbetween sodium excretion and renin secretion by the perfused kidney. Proc Soc ExpBiol Med 1975;150:728-34.36. Blair-West JR, Brook AN, Simpson PA. On the question of body fluid volume orsodium status influencing renin release. J Physiol 1977;267:321-38.37. Coote JH, Johns EJ, Macleod VH, Singer B. Effect of renal nerve stimulation, renalblood flow and adrenergic blockade on plasma renin activity in the cat. J Physiol1972;226:15-9.38. Sealey JE, Clark I, Bull MB, Laragh JH. Potassium balance and the control of reninsecretion. J Clin Invest 1970;49:2119-27.39. Henrich WL. Role of the prostaglandins in renin secretion. Kidney Int 1981;19:822-5.40. Rosenthal J, Thurnreiter M, Plaschke M, Geyer M, Reiter W, Dahlheim H. Reninlikeenzymes in human vasculature. Hypertension 1990;15:848-53.41. Doi Y, Atarashi K, Franco-Saenz R, Mulrow PJ. Effects of changes in sodium orpotassium balance, and nephrectomy, on adrenal renin and aldosterone concentrations.Hypertension 1984;6:1124-9.42. Soubrier F, Wei L, Hubert C, Clauser E, Alhenc-Gelas F, Corvol P. Molecular biology108
- Page 2 and 3:
SVEUČILIŠTE U ZAGREBUMEDICINSKI F
- Page 4 and 5:
POPIS KRATICAACEangiotenzin konvert
- Page 6 and 7:
3. ISPITANICI i METODE.............
- Page 8 and 9:
1.1. RENIN ANGIOTENZIN SUSTAV (RAS)
- Page 10 and 11:
Slika 2. "Novi" koncept klasičnog
- Page 12 and 13:
1.1.1. AngiotenzinogenSupstrat reni
- Page 14 and 15:
i renina nađene su i u neferktomir
- Page 16 and 17:
Snižena plazmatska aktivnost renin
- Page 18 and 19:
Slika 3. Shematski prikaz krvožiln
- Page 20 and 21:
Izvanplućna konverzija angiotenzin
- Page 22 and 23:
Radovi Osborna i Studera (65,66) i
- Page 24 and 25:
Naša su istraživanja pokazala da
- Page 26 and 27:
1.1.7. Angiotenzin (1-7)Angiotenzin
- Page 28 and 29:
(114,115). Sve je više dokaza za p
- Page 30 and 31:
Slika 6. Mehanizam djelovanja endot
- Page 32 and 33:
Strukturno vrlo sličan ljudskim en
- Page 34 and 35:
afinitetom receptora (135). Cistein
- Page 36 and 37:
Uloga endotelina u patofiziologiji
- Page 38 and 39:
1.2.3.1. Učinci na kardiovaskularn
- Page 40 and 41:
1.2.4.2. Učinci ET-1 na regulaciju
- Page 42 and 43:
učinkom prostaglandin E2 relaksira
- Page 44 and 45:
subendotelijalnom prostoru. Naime,
- Page 46 and 47:
U in vivo uvjetima, neaktivne KC zd
- Page 48 and 49:
Molekularnim pristupom u istraživa
- Page 50 and 51:
s maksimumom nakon 48 sati (nakon g
- Page 52 and 53:
ožiljka. U oba tipa odgovora prisu
- Page 54 and 55:
dva inhibitora metaloproteinaza se
- Page 56 and 57: Kao što je već prethodno istaknut
- Page 58 and 59: Sintezu ET-1 među ostalim podstič
- Page 60 and 61: 3.1. IspitaniciU istraživanje je u
- Page 62 and 63: 3.2.2.Ultrazvučna pretraga i dople
- Page 64 and 65: Slika 10. Indeks otpora (RI) protok
- Page 66 and 67: 4. REZULTATI67
- Page 68 and 69: Tablica 7. Značajniji laboratorijs
- Page 70 and 71: Serumske aktivnosti ACE, serumske k
- Page 72 and 73: Indeks otpora (RI) u jetrenoj arter
- Page 74 and 75: Granične vrijednosti serumske akti
- Page 76 and 77: Slika 16. Prikaz granične vrijedno
- Page 78 and 79: Slika 18. Prikaz granične vrijedno
- Page 80 and 81: Slika 20. Prikaz serumske koncentra
- Page 82 and 83: Slika 22. Prikaz serumske aktivnost
- Page 84 and 85: 5. RASPRAVA85
- Page 86 and 87: dinamičke sastavnice koja je modif
- Page 88 and 89: Poznato je da u ovih bolesnika rast
- Page 90 and 91: ET-1 preko ET A receptora smješten
- Page 92 and 93: važan je modulator vaskularnog tla
- Page 94 and 95: Nije jasan razlog ovakvim disonantn
- Page 96 and 97: 1. Serumska aktivnost ACE i serumsk
- Page 98 and 99: Dosadašnja istraživanja su pokaza
- Page 100 and 101: korištenja ovih doplerskih paramet
- Page 102 and 103: Former research showed elevated val
- Page 104 and 105: 9. L I T E R A T U R A105
- Page 108 and 109: of the angiotensin I-converting enz
- Page 110 and 111: diabetes type, state of metabolic c
- Page 112 and 113: medulla. Am J Physiol 2002;283:H181
- Page 114 and 115: 119. Kohno M, Ikeda M, Jonchi M, Ho
- Page 116 and 117: expressing the human ETA or ETB rec
- Page 118 and 119: 170. Gandhi CR, Stephenson K, Olson
- Page 120 and 121: 1998;18:629-38.198. Sato E, Simpson
- Page 122 and 123: esponse of α2(I) collagen to trans
- Page 124 and 125: Primary rat and mouse hepatic stell
- Page 126 and 127: Plasma endothelin levels in cirrhot
- Page 128 and 129: 10. Ž I V O T O P I S129